Oral calcitonin

Current Osteoporosis Reports

Volumn 10, Issue 1, 2012, Pages 80-85

  Maricic, Michael J ^a  

^a Catalina Pointe Rheumatology   (United States)

Author keywords

Calcitonin; Fracture; Oral; Osteoarthritis; Osteoporosis

Indexed keywords

8 (N 2HYDROXY 5CHLORO BENZOYL AMINO CAPRYLIC ACID); CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DRUG CARRIER; PLACEBO; SALCATONIN; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT; CALCITONIN; NOSE SPRAY;

AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CALCIUM HOMEOSTASIS; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; KNEE OSTEOARTHRITIS; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RHINITIS; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; VERTEBRA FRACTURE; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CLINICAL TRIALS AS TOPIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; NASAL SPRAYS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84862252920     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0084-x     Document Type: Article

References (28)

1. Copp DH, Cameron EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science. 1961;134:2038.
2. Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use [editorial]. Calcif Tissue Int. 1995;57:405-8.
3. Buclin R, Rochat MC, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Min Res. 2002;17:1478-85. (Pubitemid 34803831)
4. Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999;42:1159-67. (Pubitemid 29268952)
5. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425-30. (Pubitemid 41160502)
6. Nicholson G, Moseley J, Sexton P, Mendelsohn F, Martin T. Abundant calcitonin receptors in isolate rat osteoclasts, biochemical, and autoradiographic characterization. J Clin Invest. 1986;78:355-60. (Pubitemid 16074070)
7. Buclin T, Randin J, Jacquet A, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int. 1987;41(5):252-8.
8. Ralston SH, Coleman R, Fraser WD, et al. Medical management of hypercalcemia. Calcif Tissue Int. 2004;74(1):1-11. (Pubitemid 38166598)
9. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ. 1992;305(6862):1124- 8.
10. Overgaard K, Agnusdei D, Hansen MA, et al. Dose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1991;72:344-9. (Pubitemid 21921697)
11. Chesnut CH, Silverman SL, Andriano K, for the Proof Study Group, et al. Prospective. Randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: the PROOF study. Am J Med. 2000;109:267-76.
12. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;851:231-6. (Pubitemid 32268819)
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-45. (Pubitemid 29384151)
14. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1727-38.
15. Karsdal MA, Henriksen K, Bay-Jensen AC, et al.Lessons learned from the development of oral calcitonin : The first tablet formulation of a protein in Phase III clinical trials. J Clin Pharmacol 2011 51: 460-71. This is an excellent review of the challenges posed in the absorption or oral peptides, and the methods developed to overcome them.
16. Henriksen K, Bay-Jensen AC, Christiansen C, et al. Oral salmon calcitonion- pharmacology in osteoporosis. Expert Opin Biol Ther 2010;10:1617-29. This is a comprehensive overview of the clinical development of oral calcitonin.
17. Leone-Bay A, McInnes C, Wang N, et al. Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J Med Chem. 1995;38:4257-62.
18. Leone-Bay A, Santiago N, Achan D, et al. N-acylated alpha amino acids as novel oral delivery agents for proteins. J Med Chem. 1995;38:4263-9.
19. Karsdal MA, Byrjalsen I, Riis BJ, et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol. 2008;8:5.
20. Karsdal MA, Byrjalsen I, Henriksen K, et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol. 2010;66:29-37.
21. Karsdal MA, Byrjalsen I, Riis BJ, et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol. 2008;8:12.
22. Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19:1531-8. (Pubitemid 41094356)
23. Russo LA, Lau E, Tang H, et al. Efficacy and safety of oral salmon calcitonin in postmenopausal osteoporosis: Randomized, double-blind, placebo-controlled trial. Abstract. American Society of Bone and Mineral Research AnnualMeeting. Toronto, 2010.
24. Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage. 2008;16:638-46.
25. Kwan TS, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010;24:51-70.
26. Manicourt DH, Devogelaer JP, Azria M, et al. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact. 2005;5(3):285-93. (Pubitemid 41684177)
27. Bagger YZ, Tanko LB, Alexanderson P. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425-30. (Pubitemid 41160502)
28. Karsdal MA, Alexandersen P, Dam EB, et al. Oral calcitonin demonstrated symptom-modifying efficacy and decreased cartilage volume loss: Results from a 2-year Phase 3 trial in patients with osteoarthritis of the knee. Abstract L9. American College of Rheumatology National Meeting. Chicago. 2011